TL;DR
A Nov. 6, 2026, MedPage Today roundup highlighted three developments: clinicians are being urged not to overlook a small breast cancer risk associated with some menopause hormone therapies; ASCO projects a roughly 2% Medicare pay cut for oncologists in 2027; and UCLA Health reports routine imaging may not benefit women treated for ductal carcinoma in situ with double mastectomy. The source does not provide detailed study findings or policy documents for these items, so the scope and evidence behind each remain limited in the report.
A Nov. 6, 2026, MedPage Today roundup highlighted three developments for cancer care: a warning not to overlook a small breast cancer risk linked to certain menopause hormone therapies, an Association for Clinical Oncology (ASCO) estimate of a roughly 2% Medicare pay cut for oncologists in 2027, and a UCLA Health report that routine breast imaging may not benefit some women after double mastectomy for ductal carcinoma in situ. The roundup offers brief summaries rather than full study or policy details, leaving important questions about evidence, eligibility and implementation unanswered.
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The hormone therapy item, citing the New York Times, says doctors are warning that certain hormonal treatments used for menopause symptoms carry a small increase in breast cancer risk that should not be overlooked. The roundup does not identify the specific therapies, describe the size of the risk, or set out how it varies by treatment duration or patient characteristics. Separately, it reports that the FDA removed boxed warnings about breast cancer, cardiovascular disease and dementia from the labels of three estrogen patches, citing The Guardian. The source does not give the patch names or the FDA’s rationale.
On payment, the roundup says ASCO expects a roughly 2% cut to payments for oncologists treating Medicare patients under the 2027 Physician Fee Schedule from the Centers for Medicare & Medicaid Services. This is ASCO’s characterization of the proposed or scheduled payment effect in the roundup; it does not include the fee schedule’s underlying calculations, details by service, or the status of any formal review or revisions.
The third item, attributed to UCLA Health, says women who had a double mastectomy to treat ductal carcinoma in situ (DCIS) may not benefit from routine mammograms or other breast imaging. The short summary does not describe the evidence, patient group or exceptions, and it does not say imaging should be stopped for every person with this history. Decisions about follow-up should be made with a treating clinician based on the individual’s circumstances.
How the Three Updates Affect Care
Together, the items touch on decisions patients and clinicians face at different points in cancer care: managing menopause symptoms, financing oncology services and choosing follow-up after surgery. The hormone therapy warning underscores that patients may need to weigh symptom relief against risks that can differ across treatments and individuals. The reported removal of boxed warnings from certain patch labels also makes it important to distinguish a change in product labeling from evidence that all hormone therapy is risk-free.
The projected Medicare payment reduction matters because oncology practices rely on reimbursement to deliver care to older patients. ASCO says it is monitoring the potential effects, but the roundup provides no assessment of how a 2% change could affect staffing, appointment access or particular services. Those consequences should not be treated as established from the figure alone.
For patients after double mastectomy for DCIS, the imaging report may prompt questions about whether routine mammograms or other scans are useful. The summary does not provide a new universal screening rule. It points instead to a possible lack of benefit in the described group, making the underlying evidence and the patient’s treatment history important to any follow-up decision.
Products Worth Considering
Therabody Theragun Relief Massage Gun, 3-Speed, Navy
Withings Sleep Under-Mattress Sleep Tracking Pad
Garmin Venu 4 GPS Smartwatch, 45 mm, Slate with Black Silicone Band
As an affiliate, we earn on qualifying purchases.
The Reporting Behind These Items
The three developments appeared among a broader cancer-related news roundup published by MedPage Today on Nov. 6, 2026. Its short entries draw on other outlets and organizations: the hormone therapy warning is attributed to the New York Times, the FDA label change to The Guardian, and the post-mastectomy imaging item to UCLA Health. The payment estimate is attributed to ASCO and refers to the CMS 2027 Physician Fee Schedule.
The roundup also mentions other cancer-related news, including a further FDA review of a drug application for liver cancer treatment, a bankruptcy filing by Karyopharm Therapeutics, and research findings across several cancer types. Those items are separate developments; the three highlighted here are connected by their potential relevance to treatment choices, follow-up care and the resources available to oncology practices. The roundup’s format is brief, so it serves as a pointer to developments rather than a substitute for the underlying announcements or research.
“Doctors are warning not to overlook the small increase in breast cancer risk associated with certain hormonal therapies for treating menopause symptoms.”
— MedPage Today, summarizing the hormone therapy report
Evidence and Policy Details Pending
The source gives no numerical estimate for the breast cancer risk linked to the hormonal therapies, and it does not identify the drugs, doses, duration of use or patient groups involved. It also does not explain the FDA’s decision to remove boxed warnings from three estrogen patches, identify the products, or say how the change affects prescribing information beyond those labels.
For the proposed 2027 Medicare payment change, the roundup does not include CMS’s payment tables or clarify whether the 2% figure refers to a particular service, a broader average, or a final adjustment. The potential effect on practices and patient access is not established. For imaging after double mastectomy, the entry does not describe the study design, outcomes, follow-up period or which patients might still need imaging. The evidence behind each short item must be reviewed before drawing broader conclusions.
Next Steps for Patients and Practices
Readers seeking decisions about menopause treatment should discuss the specific therapy and personal risk factors with a clinician, rather than applying a general warning to every hormonal treatment. The FDA label change may inform those conversations, but the source does not provide enough detail to determine its practical effect. People treated for DCIS with double mastectomy should ask their care team what follow-up is appropriate for their individual history; the roundup does not establish a one-size-fits-all imaging plan.
For oncology practices, the next relevant information is the final and detailed CMS 2027 Physician Fee Schedule, along with ASCO’s further assessment of its effects. The source reports that ASCO is monitoring possible impacts on cancer care delivery but gives no timetable or specific forecast. Until supporting documents and fuller reporting are available, the stated payment change and the clinical implications of the other items should be treated within the limits of the brief summaries.
Key Questions
Which menopause hormone therapies are linked to the reported breast cancer risk?
The roundup does not name the therapies. It says only that certain hormonal treatments for menopause symptoms are associated with a small increase in risk, citing a New York Times report.
Did the FDA remove warnings from all estrogen products?
No. The source says the FDA removed boxed warnings about breast cancer, cardiovascular disease and dementia from the labels of three estrogen patches. It does not identify them or report a change to every estrogen product.
What does the roughly 2% oncology pay cut refer to?
ASCO said oncologists treating Medicare patients would face a roughly 2% cut under the 2027 CMS Physician Fee Schedule. The roundup does not provide calculations or a breakdown by service.
Should everyone who has had a double mastectomy for DCIS stop having breast imaging?
No such general instruction is established in the source. UCLA Health’s reported finding says routine mammograms or other imaging may not benefit women in the described group. Patients should ask their care team about follow-up based on their individual circumstances.
Source: medpagetoday.com
